Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis

We compared Simoa(TM) and Ella(TM) immunoassays to assess serum neurofilament‐light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The Ella(TM) instrument overestimated values by 17%, but as th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauthier, Audrey, Viel, Sébastien, Perret, Magali, Brocard, Guillaume, Casey, Romain, Lombard, Christine, Laurent‐Chabalier, Sabine, Debouverie, Marc, Edan, Gilles, Vukusic, Sandra, Lebrun‐Frénay, Christine, De Sèze, Jérôme, Laplaud, David Axel, Castelnovo, Giovanni, Gout, Olivier, Ruet, Aurélie, Moreau, Thibault, Casez, Olivier, Clavelou, Pierre, Berger, Eric, Zephir, Hélène, Trouillet‐Assant, Sophie, Thouvenot, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108418/
https://www.ncbi.nlm.nih.gov/pubmed/33830650
http://dx.doi.org/10.1002/acn3.51355
Descripción
Sumario:We compared Simoa(TM) and Ella(TM) immunoassays to assess serum neurofilament‐light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The Ella(TM) instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to Ella(TM) results. As for Simoa(TM), serum neurofilament‐light chain levels measured by Ella(TM) were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.

Ejemplares similares